A high dose of weight reduction drug drugs (higher often called its brand name) might help people lose as much as 25 % of body weight-without the chance of severe unwanted effects. These results are based on the outcomes of two recent clinical trials published.
Has proved to be effective in semaglotide Helping people lose weight. But weight reduction is a plateau after almost a yr of use – even when probably the most approved dose of medication takes place. This implies that patients cannot reach their weight reduction goals.
Therefore, researchers got here out to grasp whether a high dose may very well be effective without the chance of severe unwanted effects.
I The first trialResearchers studied the effect of a 7.2mg dose of semaglotide in obese adults. This is currently 3 times the approved 2.4mg dose of Vegovo. Participants were assigned to either a high dose, standard dose or placebo medicine for a period of 72 weeks per week.
Participants were also told to scale back the quantity of calories day by day by 500 calories day by day and increase the quantity of physical activity every week (geared toward about 150 150 minutes).
Participants who received 7.2mg dose were lost about 21 % of their body weight on average. Participants who took Placebo fell only 2.4 % of their body weight. These figures are based on individuals who fully followed the treatment.
About 333 % of the participants on the high dose also experience high levels of weight reduction. This is double the proportion of the usual food group, where only this degree of weight reduction is achieved under only 17 %.
Participants who used semaglotide also saw more improvement of their cardioometabolic health than those that only achieved Placebo.
As will be expected, unwanted effects were more common in individuals who take more dose of semaglotide than low -dose -taking. The most typical unwanted effects were gastrointestinal problems, reminiscent of nausea or diarrhea. Due to those gastrointestinal problems, about 3 % of participants use high doses using high doses and a couple of % of participants stop using drugs using standard doses.
A The second case Then it was investigated what the effect of a high dose of semaglotide will probably be in individuals with type 2 diabetes.
It is well -established that folks with type 2 diabetes Lose underweight Diabetes on semaglotide in comparison with people. Currently it will not be known why that is. Therefore, the second trial tried to grasp whether individuals with type 2 diabetes would have a big effect on weight reduction even on weight reduction.
Adgrapho/ shutter stock
This time he recruited 512 participants with obesity, who also had type 2 diabetes. He used the identical study design within the previous study as he did.
7.2 mg was treated with semaglotide, losing greater than 13 % of his body weight. The standard food group has lost about 10 % of its body weight, while the Placebo Group has lost lower than 4 % of its body weight.
Beyond weight reduction, a 7.2mg dose of semuglotide improved the measurement in metabolic health. On average, the waist tawaaf decreased 6.5 cm in comparison with the Placebo Group. Blood glucose levels (HBA1C, a measure of diabetes control) also decreased by about 2 % in high -dose.
The semuglotide collectors once more had probably the most experienced unwanted effects in gastrointestinal problems.
Patient advantage
Semiglotide promotes weight reduction by imitating the body's natural GLP-1 hormone, which helps to control blood sugar and appetite. These drugs work on the brain paths that control the balance of energy and the quantity of food, which reduces the sensation of appetite and the sensation of appetite and before it. This might help people eat less, which loses weight.
Excessive doses of smuglotide cause chubby loses by activating the brain areas that control appetite, leading to lack of appetite and increases the emotions of entireness. They also decelerate the stomach more effectively, helping to scale back the whole amount of food.
The results of those two trials suggest that using more dose of semaglotide is protected and really effective. When it involves handling their weight and controlling their blood sugar, it offers maximum options for patients able to using high doses of semiglood. It also gives an choice to individuals who cannot reply to an ordinary 2.4 mg dose or can have a weight reduction level.
These results also show that semaglotide can compete against other weight reduction drugs, reminiscent of Terzptide. Earlier in the top trial trial, 10 grams of terozepitide dose – -15g of dose resulting from a 20 % reduction in body weight -while an ordinary dose of semaglotide is simply roughly approximatel 14 % damage to body weight. But now recent studies suggest that top dose of semoglotide can result in a comparative level of weight reduction.
These results can even raise questions on whether food increases will be the usual of future care within the treatment of obesity.